We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK has unveiled a proposal that would empower the Medicines and Healthcare Products Regulatory Agency (MHRA) to temporarily authorize effective COVID-19 vaccines while they are still under review. Read More
HHS denied Friday that its termination of a prominent public relations consultant had anything to do with the recent controversy over the FDA Commissioner’s presentation on convalescent plasma as a COVID-19 treatment, while the FDA refused to shed any light on the reported firing of its head spokesperson. Read More
The FDA has detailed how the agency’s Office of Generic Drugs (OGD) will handle requests for drug application ownership transfers in a new manual of policies and procedures (MAPP). Read More
A new bill introduced by Sen. Gary Peters (D-Mich.) would give the FDA the authority to recall unsafe drug products, a power it currently does not have. Read More
The Department of Justice (DOJ) has charged a Teva Pharmaceuticals subsidiary with allegedly conspiring to rig prices for generic drugs, making it the seventh drugmaker to be indicted as part of an ongoing probe. Read More
Three ranking Democrats have asked a Virginia-based consulting firm to reveal details of its government contract for Operation Warp Speed’s chief adviser Moncef Slaoui, citing concerns that the contract allows the former pharma executive to skirt ethics rules and avoid disclosing potential conflicts of interest. Read More
The Trump administration’s Aug. 24 deadline has come and gone for the pharma industry to come up with a drug pricing strategy that would prevent a threatened executive order by President Trump from going into effect — but the White House and big pharma have remained silent. Read More